Poly Medicure Q3 FY26 net profit drops 17 percent despite 16 percent revenue growth; EBITDA margins contract amid higher ...
Poly Medicure's revenue growth was steady during the December quarter but its margins and profit took a hit. The stock is ...
Medicure Inc’s (TSXV:MPH) most recent return on equity was a substandard 14.25% relative to its industry performance of 15.24% over the past year. MPH’s results could indicate a relatively inefficient ...
Medicure (CVE:MPH) has had a great run on the share market with its stock up by a significant 33% over the last three months. As most would know, fundamentals are what usually guide market price ...
Trade Brains on MSN
Why did Poly Medicure shares crash 44% despite strong long term growth?
India, Feb. 3 -- Poly Medicure, a key player in India's medical devices sector, has recently faced significant stock weakness ...
WINNIPEG, Dec. 17, 2019 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the completion of the ...
I am writing today to help inform people who are new to the stock market and want to begin learning the link between company’s fundamentals and stock market performance. Medicure Inc (CVE:MPH) ...
WINNIPEG, MB, June 15, 2020 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, is pleased to announce that on ...
WINNIPEG, MB, Aug. 20, 2020 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a pharmaceutical company, today announced the termination of the marketing and ...
WINNIPEG, MANITOBA--(Marketwire - Jan. 30, 2012) - Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE:MPH.V - News)(PINKSHEETS:MCUJ.PK - News) is pleased to announce its plans for a new clinical ...
Medicure's initial ownership interest and option rights were obtained for its lead role in structuring and participating in a majority interest purchase and financing of Apicore that occurred on July ...
WINNIPEG, Medicure Inc., a cardiovascular pharmaceutical company, is pleased to announce that the United States Food and Drug Administration ("FDA") has approved its Abbreviated New Drug Application ( ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results